GlaxoSmithKline continues to offer more of its key global products in developing nations under a tiered approach to pricing. The company has now launched its anti-angiogenic, multi-targeted tyrosine kinase inhibitor Votrient (pazopanib), and the thrombocytopenia treatment, Revolade (eltrombopag), on the Indian market at about 25-30% of their US prices.
Votrient, which is indicated for advanced renal cell carcinoma (RCC), will cost about Rs58,000 ($1,303) per month, while Revolade will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?